Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Комплексная оценка характера эзофагеальной ацидификации и моторной функции у пациентов с пищеводом Баррета на фоне применения антисекреторной терапии
Комплексная оценка характера эзофагеальной ацидификации и моторной функции у пациентов с пищеводом Баррета на фоне применения антисекреторной терапии
Маев И.В., Баркалова Е.В., Андреев Д.Н., Овсепян М.А., Мовтаева П.Р., Зайратьянц О.В. Комплексная оценка характера эзофагеальной ацидификации и моторной функции у пациентов с пищеводом Баррета на фоне применения антисекреторной терапии. Терапевтический архив. 2021;93(12):1463–1469. DOI: 10.26442/00403660.2021.12.201278
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Определение предикторов недостаточной эффективности ингибиторов протонной помпы на основе параметров суточной рН-импедансометрии и особенностей моторики пищевода у пациентов с пищеводом Баррета (ПБ).
Материалы и методы. Обследованы 17 пациентов с гистологически верифицированным ПБ, находящихся на кислотосупрессивной терапии. Всем пациентам проводились суточная рН-импедансометрия и манометрия пищевода высокого разрешения.
Результаты. По данным суточной рН-импедансометрии 1-ю группу составили 11 пациентов с адекватным ответом на антисекреторную терапию, 2-ю группу – 6 пациентов с недостаточной кислотосупрессией, 5 из которых не имели клинических проявлений. Общее количество рефлюксов в среднем составило 52 и 91 соответственно в 1 и 2-й группах. Среднее количество кислых рефлюксов в 1-й группе составило 4,36, во 2-й группе – 40,5. Среднее количество некислых рефлюксов преобладало у пациентов 2-й группы, составляя в среднем 58, а в 1-й группе в среднем этот показатель был 47. Согласно результатам манометрии пищевода высокого разрешения при оценке структуры и функции пищеводно-желудочного перехода нарушения выявлены у 6 из 17 пациентов. Расстройства двигательной функции грудного отдела пищевода выявлены у 10 пациентов из 17. Тонус нижнего пищеводного сфинктера у пациентов 1-й группы оказался достоверно более высоким в сравнении с больными, составляющими 2-ю группу.
Заключение. У ряда пациентов с ПБ отмечается недостаточная эффективность антисекреторной терапии, что может не проявлять себя клинически и тем самым повышать риск прогрессирования. Выявлена тенденция к более частым моторным нарушениям в группе с недостаточной эффективностью антисекреторной терапии, а также достоверно более низкий тонус нижнего пищеводного сфинктера, что может быть потенциальным предиктором субоптимальной эффективности антисекреторной терапии.
Ключевые слова: пищевод Баррета, суточная рН-импедансометрия, манометрия высокого разрешения
Materials and methods. 17 patients with histologically verified Barrett's esophagus undergoing acid-suppressive therapy were examined. All patients underwent 24-hours pH-impedance and high-resolution esophageal manometry.
Results. According to daily pH-impedance, group 1 consisted of 11 patients with an adequate response to antisecretory therapy, group 2 – 6 patients with insufficient effectiveness of antisecretory therapy, 5 of whom had no clinical manifestations. The total number of reflux averaged 52 and 91, respectively, in groups 1 and 2. The average number of acid reflux in group 1 was 4.36, in group 2 – 40.5. The average number of non-acid reflux prevailed in patients of group 2, averaging 58, compared with group 1, where the average was 47. According to the results of high-resolution esophageal manometry, when assessing the structure and function of the esophageal-gastric junction, violations were detected in 6 out of 17 patients. Disorders of the motor function of the thoracic esophagus were detected in 10 out of 17 patients. The tone of the lower esophageal sphincter in group 1 patients was significantly higher in comparison with patients in group 2.
Conclusion. A number of patients with Barrett's esophagus have insufficient effectiveness of antisecretory therapy, which may not manifest itself clinically and thereby increase the risk of progression. There was a tendency to more frequent motor disorders in the group with insufficient effectiveness of antisecretory therapy, as well as significantly lower tone of the lower esophageal sphincter, which may be a potential predictor of suboptimal effectiveness of antisecretory therapy.
Keywords: Barrett's esophagus, 24-hours pH-impedance, high-resolution manometry
Материалы и методы. Обследованы 17 пациентов с гистологически верифицированным ПБ, находящихся на кислотосупрессивной терапии. Всем пациентам проводились суточная рН-импедансометрия и манометрия пищевода высокого разрешения.
Результаты. По данным суточной рН-импедансометрии 1-ю группу составили 11 пациентов с адекватным ответом на антисекреторную терапию, 2-ю группу – 6 пациентов с недостаточной кислотосупрессией, 5 из которых не имели клинических проявлений. Общее количество рефлюксов в среднем составило 52 и 91 соответственно в 1 и 2-й группах. Среднее количество кислых рефлюксов в 1-й группе составило 4,36, во 2-й группе – 40,5. Среднее количество некислых рефлюксов преобладало у пациентов 2-й группы, составляя в среднем 58, а в 1-й группе в среднем этот показатель был 47. Согласно результатам манометрии пищевода высокого разрешения при оценке структуры и функции пищеводно-желудочного перехода нарушения выявлены у 6 из 17 пациентов. Расстройства двигательной функции грудного отдела пищевода выявлены у 10 пациентов из 17. Тонус нижнего пищеводного сфинктера у пациентов 1-й группы оказался достоверно более высоким в сравнении с больными, составляющими 2-ю группу.
Заключение. У ряда пациентов с ПБ отмечается недостаточная эффективность антисекреторной терапии, что может не проявлять себя клинически и тем самым повышать риск прогрессирования. Выявлена тенденция к более частым моторным нарушениям в группе с недостаточной эффективностью антисекреторной терапии, а также достоверно более низкий тонус нижнего пищеводного сфинктера, что может быть потенциальным предиктором субоптимальной эффективности антисекреторной терапии.
Ключевые слова: пищевод Баррета, суточная рН-импедансометрия, манометрия высокого разрешения
________________________________________________
Materials and methods. 17 patients with histologically verified Barrett's esophagus undergoing acid-suppressive therapy were examined. All patients underwent 24-hours pH-impedance and high-resolution esophageal manometry.
Results. According to daily pH-impedance, group 1 consisted of 11 patients with an adequate response to antisecretory therapy, group 2 – 6 patients with insufficient effectiveness of antisecretory therapy, 5 of whom had no clinical manifestations. The total number of reflux averaged 52 and 91, respectively, in groups 1 and 2. The average number of acid reflux in group 1 was 4.36, in group 2 – 40.5. The average number of non-acid reflux prevailed in patients of group 2, averaging 58, compared with group 1, where the average was 47. According to the results of high-resolution esophageal manometry, when assessing the structure and function of the esophageal-gastric junction, violations were detected in 6 out of 17 patients. Disorders of the motor function of the thoracic esophagus were detected in 10 out of 17 patients. The tone of the lower esophageal sphincter in group 1 patients was significantly higher in comparison with patients in group 2.
Conclusion. A number of patients with Barrett's esophagus have insufficient effectiveness of antisecretory therapy, which may not manifest itself clinically and thereby increase the risk of progression. There was a tendency to more frequent motor disorders in the group with insufficient effectiveness of antisecretory therapy, as well as significantly lower tone of the lower esophageal sphincter, which may be a potential predictor of suboptimal effectiveness of antisecretory therapy.
Keywords: Barrett's esophagus, 24-hours pH-impedance, high-resolution manometry
Полный текст
Список литературы
1. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97
[Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97 (in Russian)]. DOI:10.22416/1382-4376-2020-30-4-70-97
2. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа, 2019 [Maev IV, Busarova GA, Andreev DN. Bolezni pishchevoda. Moscow: GEOTAR-Media, 2019 (in Russian)].
3. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., и др. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4-11 [Maev IV, Andreev DN, Kucheryavyy YA, et al. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(8):4-11]. DOI:10.26442/00403660.2019.08.000387
4. Cook MB, Thrift AP. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2021;31(1):1-26. DOI:10.1016/j.giec.2020.08.001
5. Mohy-Ud-Din N, Krill TS, Shah AR, et al. Barrett's esophagus: What do we need to know? Dis Mon. 2020;66(1):100850.
DOI:10.1016/j.disamonth.2019.02.003
6. ASGE standards of practice committee; Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-59.e2. DOI:10.1016/j.gie.2019.05.012
7. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-17.e1. DOI:10.1016/j.gie.2019.05.030
8. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Ожирение и коморбидность. М., 2016 [Maev IV, Kucheryavyy YuA, Andreev DN. Ozhirenie i komorbidnost'. Moscow, 2016 (in Russian)].
9. Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929-36. DOI:10.1055/s-2005-870433
10. Bertani H, Frazzoni M, Dabizzi E, et al. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci. 2013;58(1):188-93. DOI:10.1007/s10620-012-2332-z
11. Зайратьянц О.В., Маев И.В., Смольянникова В.А., и др. Патологическая анатомия пищевода Баррета. Архив патологии. 2011;73(3):21-6 [Zairat'iants OV, Maev IV, Smol'iannikova VA, et al. Pathologic anatomy of Barrett's esophagus. Arkhiv patologii. 2011;73(3):21-6 (in Russian)].
12. Eusebi LH, Cirota GG, Zagari RM, et al. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and metaanalysis. Gut. 2021;70(3):456-63. DOI:10.1136/gutjnl-2020-321365
13. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., и др. Аденокарцинома пищевода: факторы риска и современные стратегии скрининга. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):4-12 [Mayev IV, Andreyev DN, Kucheryavy YuA, et al. Esophageal adenocarcinoma: risk factors and modern screening strategy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):4-12 (in Russian)].
DOI:10.22416/1382-4376-2017-27-2-4-12
14. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149-58.
DOI:10.1002/cncr.27834
15. Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070-4. DOI:10.1136/gut.2003.028076
16. Tanţău M, Laszlo M, Tanţău A. Barrett's Esophagus – State of the Art. Chirurgia (Bucur). 2018;113(1):46-60. DOI:10.21614/chirurgia.113.1.46
17. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(1):3-10.e3. DOI:10.1016/j.gie.2019.07.037
18. Fitzgerald RC, di Pietro M, Ragunath K, et al.; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut.
2014;63(1):7-42. DOI:10.1136/gutjnl-2013-305372
19. Shaheen NJ, Falk GW, Iyer PG, et al.; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111(1):30-50. DOI:10.1038/ajg.2015.322
20. Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021;147(9):2681-91. DOI:10.1007/s00432-021-03544-3
21. Маев И.В., Баркалова Е.В., Кучерявый Ю.А., и др. Паттерны эзофагеальной ацидификации и нарушений моторики при заболеваниях пищевода. Вест. РАМН. 2020;75(2):96-105 [Maev IV, Barkalova EV, Kucheryavyy YA, et al. Patterns of esophageal acidification and impairment of esophageal motility in gastroesophageal reflux disease and Barrett’s esophagus. Annals of the Russian Academy of Medical Sciences. 2020;75(2):96-105 (in Russian)]. DOI:10.15690/vramn1211
22. Маев И.В., Баркалова Е.В., Овсепян М.А., и др. Возможности рН-импедансометрии и манометрии высокого разрешения при ведении пациентов с рефрактерной гастроэзофагеальной рефлюксной болезнью. Терапевтический архив. 2017;89(2):76-83 [Maev IV, Barkalova EV, Ovsepyan MA, et al. Possibilities of pH impedance and high-resolution manometry in managing patients with refractory gastroesophageal reflux disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):76-83 (in Russian)]. DOI:10.17116/terarkh201789276-83
23. Маев И.В., Зайратьянц О.В., Кучерявый Ю.А., и др. Клиническое значение функциональных методов исследования у пациентов с пищеводом Барретта. Доказательная гастроэнтерология. 2020;1:41-9 [Maev IV, Zairat’yants OV, Kucheriavyi IuA, et al. The importance of esophageal function tests in patients with Barrett’s esophagus. Russian Journal of Evidence-Based Gastroenterology. 2020;9(1):41-9 (in Russian)]. DOI:10.17116/dokgastro2020901141
24. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. М.: ШИКО, 2011 [Ivashkin VT, Maev IV, Trukhmanov AS. Pishchevod Barreta. Moscow: Shiko, 2011 (in Russian)].
25. Fass R, Teramoto O, Kurin M, et al. Esophageal Function Abnormalities in Patients With Barrett's Esophagus. J Clin Gastroenterol. 2020;54(6):485-92. DOI:10.1097/MCG.0000000000001358
26. Saito M, Koike T, Nakagawa K, et al. Strong Intra-Esophageal Reflux May Contribute to the Development of Barrett's Adenocarcinoma and Affect the Localization. Digestion. 2020;101(6):752-60. DOI:10.1159/000502377
27. Bazin C, Benezech A, Alessandrini M, et al. Esophageal Motor Disorders Are a Strong and Independant Associated Factor of Barrett's Esophagus. J Neurogastroenterol Motil. 2018;24(2):216-25. DOI:10.5056/jnm17090
28. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. DOI:10.1111/nmo.13330
29. Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet. Clin Gastroenterol Hepatol. 2020;18(4):767-76.
DOI:10.1016/j.cgh.2019.07.015
30. Kahrilas P, Bredenoord A, Fox M, et al.; International High Resolution Manometry Working Group. The Сhicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160‐74. DOI:10.1111/nmo.12477
31. Евсютина Ю.В., Трухманов А.С. Алгоритм ведения пациентов с рефрактерной формой ГЭРБ. РМЖ. 2015;28:1682-3 [Yevsyutina YuV, Trukhmanov AS. Management of refractory GERD patients. RMJ. 2015;28:1682-3 (in Russian)].
32. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Внутрипищеводная рН-импедансометрия в диагностике ГЭРБ. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013;2:4-12 [Kaybysheva VO, Storonova OA, Trukhmanov AS, Ivashkin VT. Intraesophageal pH-impedance measurement in diagnosis of GERD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;2:4-12 (in Russian)].
33. Lottrup C, Krarup AL, Gregersen H, et al. Patients with Barrett’s esophagus are hypersensitive to acid but hyposensitive to other stimuli compared with healthy controls. Neurogastroenterol Motil. 2017;29(4). DOI:10.1111/nmo.12992
34. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12. DOI:10.1136/gut.37.1.7
35. Brandt MG, Darling GE, Miller L. Symptoms, acid exposure and motility in patients with Barrett’s esophagus. Can J Surg. 2004;47:47-51.
36. Grade A, Pulliam G, Johnson C, et al. Reduced chemoreceptor sensitivity in patients with Barrett’s esophagus may be related to age and not to the presence of Barrett’s epithelium. Am J Gastroenterol. 1997;92:2040-3.
37. Fletcher J, Gillen D, Wirz A, et al. Barrett’s esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions. Am J Gastroenterol. 2003;98:1480-6. DOI:10.1111/j.1572-0241.2003.07543.x
38. Weijenborg PW, Smout A, Krishnadath KK, et al. Esophageal sensitivity to acid in patients with Barrett’s esophagus is not related to preserved esophageal mucosal integrity. Neurogastroenterol Motil. 2017;29(7). DOI:10.1111/nmo.13066
39. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018.
DOI:10.1111/nmo.13330
40. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Манометрия высокого разрешения и новая классификация нарушений моторики пищевода. Терапевтический архив. 2018;90(5):93-100 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. High resolution manometry and new classification of esophageal motility disorders. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):93-100 (in Russian)].
DOI:10.26442/terarkh201890593-100
41. Маев И.В., Андреев Д.Н., Гончаренко А.Ю., Дичева Д.Т. Ингибиторы протонной помпы как основа лечения кислотозависимых заболеваний. Справочник поликлинического врача. 2013;7-8:42-4
[Maev IV, Andreev DN, Goncharenko AYu, Dicheva D.T. Proton pump inhibitors as the basis for the treatment of acid-related diseases.
Handbook for Practitioners Doctors. 2013;7-8:42-4 (in Russian)].
2. Maev IV, Busarova GA, Andreev DN. Bolezni pishchevoda. Moscow: GEOTAR-Media, 2019 (in Russian).
3. Maev IV, Andreev DN, Kucheryavyy YA, et al. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(8):4-11. DOI:10.26442/00403660.2019.08.000387
4. Cook MB, Thrift AP. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2021;31(1):1-26. DOI:10.1016/j.giec.2020.08.001
5. Mohy-Ud-Din N, Krill TS, Shah AR, et al. Barrett's esophagus: What do we need to know? Dis Mon. 2020;66(1):100850.
DOI:10.1016/j.disamonth.2019.02.003
6. ASGE standards of practice committee; Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-59.e2. DOI:10.1016/j.gie.2019.05.012
7. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-17.e1. DOI:10.1016/j.gie.2019.05.030
8. Maev IV, Kucheryavyy YuA, Andreev DN. Ozhirenie i komorbidnost'. Moscow, 2016 (in Russian).
9. Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929-36. DOI:10.1055/s-2005-870433
10. Bertani H, Frazzoni M, Dabizzi E, et al. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci. 2013;58(1):188-93. DOI:10.1007/s10620-012-2332-z
11. Zairat'iants OV, Maev IV, Smol'iannikova VA, et al. Pathologic anatomy of Barrett's esophagus. Arkhiv patologii. 2011;73(3):21-6 (in Russian).
12. Eusebi LH, Cirota GG, Zagari RM, et al. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and metaanalysis. Gut. 2021;70(3):456-63. DOI:10.1136/gutjnl-2020-321365
13. Mayev IV, Andreyev DN, Kucheryavy YuA, et al. Esophageal adenocarcinoma: risk factors and modern screening strategy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):4-12 (in Russian).
DOI:10.22416/1382-4376-2017-27-2-4-12
14. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149-58.
DOI:10.1002/cncr.27834
15. Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070-4. DOI:10.1136/gut.2003.028076
16. Tanţău M, Laszlo M, Tanţău A. Barrett's Esophagus – State of the Art. Chirurgia (Bucur). 2018;113(1):46-60. DOI:10.21614/chirurgia.113.1.46
17. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(1):3-10.e3. DOI:10.1016/j.gie.2019.07.037
18. Fitzgerald RC, di Pietro M, Ragunath K, et al.; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42. DOI:10.1136/gutjnl-2013-305372
19. Shaheen NJ, Falk GW, Iyer PG, et al.; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111(1):30-50. DOI:10.1038/ajg.2015.322
20. Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021;147(9):2681-91. DOI:10.1007/s00432-021-03544-3
21. Maev IV, Barkalova EV, Kucheryavyy YA, et al. Patterns of esophageal acidification and impairment of esophageal motility in gastroesophageal reflux disease and Barrett’s esophagus. Annals of the Russian Academy of Medical Sciences. 2020;75(2):96-105 (in Russian). DOI:10.15690/vramn1211
22. Maev IV, Barkalova EV, Ovsepyan MA, et al. Possibilities of pH impedance and high-resolution manometry in managing patients with refractory gastroesophageal reflux disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):76-83 (in Russian). DOI:10.17116/terarkh201789276-83
23. Maev IV, Zairat’yants OV, Kucheriavyi IuA, et al. The importance of esophageal function tests in patients with Barrett’s esophagus. Russian Journal of Evidence-Based Gastroenterology. 2020;9(1):41-9 (in Russian). DOI:10.17116/dokgastro2020901141
24. Ivashkin VT, Maev IV, Trukhmanov AS. Pishchevod Barreta. Moscow: Shiko, 2011 (in Russian).
25. Fass R, Teramoto O, Kurin M, et al. Esophageal Function Abnormalities in Patients With Barrett's Esophagus. J Clin Gastroenterol. 2020;54(6):485-92. DOI:10.1097/MCG.0000000000001358
26. Saito M, Koike T, Nakagawa K, et al. Strong Intra-Esophageal Reflux May Contribute to the Development of Barrett's Adenocarcinoma and Affect the Localization. Digestion. 2020;101(6):752-60. DOI:10.1159/000502377
27. Bazin C, Benezech A, Alessandrini M, et al. Esophageal Motor Disorders Are a Strong and Independant Associated Factor of Barrett's Esophagus. J Neurogastroenterol Motil. 2018;24(2):216-25. DOI:10.5056/jnm17090
28. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. DOI:10.1111/nmo.13330
29. Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet. Clin Gastroenterol Hepatol. 2020;18(4):767-76. DOI:10.1016/j.cgh.2019.07.015
30. Kahrilas P, Bredenoord A, Fox M, et al.; International High Resolution Manometry Working Group. The Сhicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160‐74. DOI:10.1111/nmo.12477
31. Yevsyutina YuV, Trukhmanov AS. Management of refractory GERD patients. RMJ. 2015;28:1682-3 (in Russian).
32. Kaybysheva VO, Storonova OA, Trukhmanov AS, Ivashkin VT. Intraesophageal pH-impedance measurement in diagnosis of GERD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;2:4-12 (in Russian).
33. Lottrup C, Krarup AL, Gregersen H, et al. Patients with Barrett’s esophagus are hypersensitive to acid but hyposensitive to other stimuli compared with healthy controls. Neurogastroenterol Motil. 2017;29(4). DOI:10.1111/nmo.12992
34. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12. DOI:10.1136/gut.37.1.7
35. Brandt MG, Darling GE, Miller L. Symptoms, acid exposure and motility in patients with Barrett’s esophagus. Can J Surg. 2004;47:47-51.
36. Grade A, Pulliam G, Johnson C, et al. Reduced chemoreceptor sensitivity in patients with Barrett’s esophagus may be related to age and not to the presence of Barrett’s epithelium. Am J Gastroenterol. 1997;92:2040-3.
37. Fletcher J, Gillen D, Wirz A, et al. Barrett’s esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions. Am J Gastroenterol. 2003;98:1480-6. DOI:10.1111/j.1572-0241.2003.07543.x
38. Weijenborg PW, Smout A, Krishnadath KK, et al. Esophageal sensitivity to acid in patients with Barrett’s esophagus is not related to preserved esophageal mucosal integrity. Neurogastroenterol Motil. 2017;29(7). DOI:10.1111/nmo.13066
39. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. DOI:10.1111/nmo.13330
40. Ivashkin VT, Maev IV, Trukhmanov AS, et al. High resolution manometry and new classification of esophageal motility disorders. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):93-100 (in Russian). DOI:10.26442/terarkh201890593-100
41. Maev IV, Andreev DN, Goncharenko AYu, Dicheva D.T. Proton pump inhibitors as the basis for the treatment of acid-related diseases. Handbook for Practitioners Doctors. 2013;7-8:42-4 (in Russian).
[Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97 (in Russian)]. DOI:10.22416/1382-4376-2020-30-4-70-97
2. Маев И.В., Бусарова Г.А., Андреев Д.Н. Болезни пищевода. М.: ГЭОТАР-Медиа, 2019 [Maev IV, Busarova GA, Andreev DN. Bolezni pishchevoda. Moscow: GEOTAR-Media, 2019 (in Russian)].
3. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., и др. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4-11 [Maev IV, Andreev DN, Kucheryavyy YA, et al. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(8):4-11]. DOI:10.26442/00403660.2019.08.000387
4. Cook MB, Thrift AP. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2021;31(1):1-26. DOI:10.1016/j.giec.2020.08.001
5. Mohy-Ud-Din N, Krill TS, Shah AR, et al. Barrett's esophagus: What do we need to know? Dis Mon. 2020;66(1):100850.
DOI:10.1016/j.disamonth.2019.02.003
6. ASGE standards of practice committee; Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-59.e2. DOI:10.1016/j.gie.2019.05.012
7. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-17.e1. DOI:10.1016/j.gie.2019.05.030
8. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Ожирение и коморбидность. М., 2016 [Maev IV, Kucheryavyy YuA, Andreev DN. Ozhirenie i komorbidnost'. Moscow, 2016 (in Russian)].
9. Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929-36. DOI:10.1055/s-2005-870433
10. Bertani H, Frazzoni M, Dabizzi E, et al. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci. 2013;58(1):188-93. DOI:10.1007/s10620-012-2332-z
11. Зайратьянц О.В., Маев И.В., Смольянникова В.А., и др. Патологическая анатомия пищевода Баррета. Архив патологии. 2011;73(3):21-6 [Zairat'iants OV, Maev IV, Smol'iannikova VA, et al. Pathologic anatomy of Barrett's esophagus. Arkhiv patologii. 2011;73(3):21-6 (in Russian)].
12. Eusebi LH, Cirota GG, Zagari RM, et al. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and metaanalysis. Gut. 2021;70(3):456-63. DOI:10.1136/gutjnl-2020-321365
13. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., и др. Аденокарцинома пищевода: факторы риска и современные стратегии скрининга. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017;27(2):4-12 [Mayev IV, Andreyev DN, Kucheryavy YuA, et al. Esophageal adenocarcinoma: risk factors and modern screening strategy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):4-12 (in Russian)].
DOI:10.22416/1382-4376-2017-27-2-4-12
14. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149-58.
DOI:10.1002/cncr.27834
15. Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070-4. DOI:10.1136/gut.2003.028076
16. Tanţău M, Laszlo M, Tanţău A. Barrett's Esophagus – State of the Art. Chirurgia (Bucur). 2018;113(1):46-60. DOI:10.21614/chirurgia.113.1.46
17. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(1):3-10.e3. DOI:10.1016/j.gie.2019.07.037
18. Fitzgerald RC, di Pietro M, Ragunath K, et al.; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut.
2014;63(1):7-42. DOI:10.1136/gutjnl-2013-305372
19. Shaheen NJ, Falk GW, Iyer PG, et al.; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111(1):30-50. DOI:10.1038/ajg.2015.322
20. Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021;147(9):2681-91. DOI:10.1007/s00432-021-03544-3
21. Маев И.В., Баркалова Е.В., Кучерявый Ю.А., и др. Паттерны эзофагеальной ацидификации и нарушений моторики при заболеваниях пищевода. Вест. РАМН. 2020;75(2):96-105 [Maev IV, Barkalova EV, Kucheryavyy YA, et al. Patterns of esophageal acidification and impairment of esophageal motility in gastroesophageal reflux disease and Barrett’s esophagus. Annals of the Russian Academy of Medical Sciences. 2020;75(2):96-105 (in Russian)]. DOI:10.15690/vramn1211
22. Маев И.В., Баркалова Е.В., Овсепян М.А., и др. Возможности рН-импедансометрии и манометрии высокого разрешения при ведении пациентов с рефрактерной гастроэзофагеальной рефлюксной болезнью. Терапевтический архив. 2017;89(2):76-83 [Maev IV, Barkalova EV, Ovsepyan MA, et al. Possibilities of pH impedance and high-resolution manometry in managing patients with refractory gastroesophageal reflux disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):76-83 (in Russian)]. DOI:10.17116/terarkh201789276-83
23. Маев И.В., Зайратьянц О.В., Кучерявый Ю.А., и др. Клиническое значение функциональных методов исследования у пациентов с пищеводом Барретта. Доказательная гастроэнтерология. 2020;1:41-9 [Maev IV, Zairat’yants OV, Kucheriavyi IuA, et al. The importance of esophageal function tests in patients with Barrett’s esophagus. Russian Journal of Evidence-Based Gastroenterology. 2020;9(1):41-9 (in Russian)]. DOI:10.17116/dokgastro2020901141
24. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. М.: ШИКО, 2011 [Ivashkin VT, Maev IV, Trukhmanov AS. Pishchevod Barreta. Moscow: Shiko, 2011 (in Russian)].
25. Fass R, Teramoto O, Kurin M, et al. Esophageal Function Abnormalities in Patients With Barrett's Esophagus. J Clin Gastroenterol. 2020;54(6):485-92. DOI:10.1097/MCG.0000000000001358
26. Saito M, Koike T, Nakagawa K, et al. Strong Intra-Esophageal Reflux May Contribute to the Development of Barrett's Adenocarcinoma and Affect the Localization. Digestion. 2020;101(6):752-60. DOI:10.1159/000502377
27. Bazin C, Benezech A, Alessandrini M, et al. Esophageal Motor Disorders Are a Strong and Independant Associated Factor of Barrett's Esophagus. J Neurogastroenterol Motil. 2018;24(2):216-25. DOI:10.5056/jnm17090
28. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. DOI:10.1111/nmo.13330
29. Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet. Clin Gastroenterol Hepatol. 2020;18(4):767-76.
DOI:10.1016/j.cgh.2019.07.015
30. Kahrilas P, Bredenoord A, Fox M, et al.; International High Resolution Manometry Working Group. The Сhicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160‐74. DOI:10.1111/nmo.12477
31. Евсютина Ю.В., Трухманов А.С. Алгоритм ведения пациентов с рефрактерной формой ГЭРБ. РМЖ. 2015;28:1682-3 [Yevsyutina YuV, Trukhmanov AS. Management of refractory GERD patients. RMJ. 2015;28:1682-3 (in Russian)].
32. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Внутрипищеводная рН-импедансометрия в диагностике ГЭРБ. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013;2:4-12 [Kaybysheva VO, Storonova OA, Trukhmanov AS, Ivashkin VT. Intraesophageal pH-impedance measurement in diagnosis of GERD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;2:4-12 (in Russian)].
33. Lottrup C, Krarup AL, Gregersen H, et al. Patients with Barrett’s esophagus are hypersensitive to acid but hyposensitive to other stimuli compared with healthy controls. Neurogastroenterol Motil. 2017;29(4). DOI:10.1111/nmo.12992
34. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12. DOI:10.1136/gut.37.1.7
35. Brandt MG, Darling GE, Miller L. Symptoms, acid exposure and motility in patients with Barrett’s esophagus. Can J Surg. 2004;47:47-51.
36. Grade A, Pulliam G, Johnson C, et al. Reduced chemoreceptor sensitivity in patients with Barrett’s esophagus may be related to age and not to the presence of Barrett’s epithelium. Am J Gastroenterol. 1997;92:2040-3.
37. Fletcher J, Gillen D, Wirz A, et al. Barrett’s esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions. Am J Gastroenterol. 2003;98:1480-6. DOI:10.1111/j.1572-0241.2003.07543.x
38. Weijenborg PW, Smout A, Krishnadath KK, et al. Esophageal sensitivity to acid in patients with Barrett’s esophagus is not related to preserved esophageal mucosal integrity. Neurogastroenterol Motil. 2017;29(7). DOI:10.1111/nmo.13066
39. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018.
DOI:10.1111/nmo.13330
40. Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Манометрия высокого разрешения и новая классификация нарушений моторики пищевода. Терапевтический архив. 2018;90(5):93-100 [Ivashkin VT, Maev IV, Trukhmanov AS, et al. High resolution manometry and new classification of esophageal motility disorders. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):93-100 (in Russian)].
DOI:10.26442/terarkh201890593-100
41. Маев И.В., Андреев Д.Н., Гончаренко А.Ю., Дичева Д.Т. Ингибиторы протонной помпы как основа лечения кислотозависимых заболеваний. Справочник поликлинического врача. 2013;7-8:42-4
[Maev IV, Andreev DN, Goncharenko AYu, Dicheva D.T. Proton pump inhibitors as the basis for the treatment of acid-related diseases.
Handbook for Practitioners Doctors. 2013;7-8:42-4 (in Russian)].
________________________________________________
2. Maev IV, Busarova GA, Andreev DN. Bolezni pishchevoda. Moscow: GEOTAR-Media, 2019 (in Russian).
3. Maev IV, Andreev DN, Kucheryavyy YA, et al. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(8):4-11. DOI:10.26442/00403660.2019.08.000387
4. Cook MB, Thrift AP. Epidemiology of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2021;31(1):1-26. DOI:10.1016/j.giec.2020.08.001
5. Mohy-Ud-Din N, Krill TS, Shah AR, et al. Barrett's esophagus: What do we need to know? Dis Mon. 2020;66(1):100850.
DOI:10.1016/j.disamonth.2019.02.003
6. ASGE standards of practice committee; Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee Chair. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-59.e2. DOI:10.1016/j.gie.2019.05.012
7. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-17.e1. DOI:10.1016/j.gie.2019.05.030
8. Maev IV, Kucheryavyy YuA, Andreev DN. Ozhirenie i komorbidnost'. Moscow, 2016 (in Russian).
9. Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37(10):929-36. DOI:10.1055/s-2005-870433
10. Bertani H, Frazzoni M, Dabizzi E, et al. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci. 2013;58(1):188-93. DOI:10.1007/s10620-012-2332-z
11. Zairat'iants OV, Maev IV, Smol'iannikova VA, et al. Pathologic anatomy of Barrett's esophagus. Arkhiv patologii. 2011;73(3):21-6 (in Russian).
12. Eusebi LH, Cirota GG, Zagari RM, et al. Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and metaanalysis. Gut. 2021;70(3):456-63. DOI:10.1136/gutjnl-2020-321365
13. Mayev IV, Andreyev DN, Kucheryavy YuA, et al. Esophageal adenocarcinoma: risk factors and modern screening strategy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(2):4-12 (in Russian).
DOI:10.22416/1382-4376-2017-27-2-4-12
14. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149-58.
DOI:10.1002/cncr.27834
15. Solaymani-Dodaran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070-4. DOI:10.1136/gut.2003.028076
16. Tanţău M, Laszlo M, Tanţău A. Barrett's Esophagus – State of the Art. Chirurgia (Bucur). 2018;113(1):46-60. DOI:10.21614/chirurgia.113.1.46
17. Krishnamoorthi R, Mohan BP, Jayaraj M, et al. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2020;91(1):3-10.e3. DOI:10.1016/j.gie.2019.07.037
18. Fitzgerald RC, di Pietro M, Ragunath K, et al.; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42. DOI:10.1136/gutjnl-2013-305372
19. Shaheen NJ, Falk GW, Iyer PG, et al.; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111(1):30-50. DOI:10.1038/ajg.2015.322
20. Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021;147(9):2681-91. DOI:10.1007/s00432-021-03544-3
21. Maev IV, Barkalova EV, Kucheryavyy YA, et al. Patterns of esophageal acidification and impairment of esophageal motility in gastroesophageal reflux disease and Barrett’s esophagus. Annals of the Russian Academy of Medical Sciences. 2020;75(2):96-105 (in Russian). DOI:10.15690/vramn1211
22. Maev IV, Barkalova EV, Ovsepyan MA, et al. Possibilities of pH impedance and high-resolution manometry in managing patients with refractory gastroesophageal reflux disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):76-83 (in Russian). DOI:10.17116/terarkh201789276-83
23. Maev IV, Zairat’yants OV, Kucheriavyi IuA, et al. The importance of esophageal function tests in patients with Barrett’s esophagus. Russian Journal of Evidence-Based Gastroenterology. 2020;9(1):41-9 (in Russian). DOI:10.17116/dokgastro2020901141
24. Ivashkin VT, Maev IV, Trukhmanov AS. Pishchevod Barreta. Moscow: Shiko, 2011 (in Russian).
25. Fass R, Teramoto O, Kurin M, et al. Esophageal Function Abnormalities in Patients With Barrett's Esophagus. J Clin Gastroenterol. 2020;54(6):485-92. DOI:10.1097/MCG.0000000000001358
26. Saito M, Koike T, Nakagawa K, et al. Strong Intra-Esophageal Reflux May Contribute to the Development of Barrett's Adenocarcinoma and Affect the Localization. Digestion. 2020;101(6):752-60. DOI:10.1159/000502377
27. Bazin C, Benezech A, Alessandrini M, et al. Esophageal Motor Disorders Are a Strong and Independant Associated Factor of Barrett's Esophagus. J Neurogastroenterol Motil. 2018;24(2):216-25. DOI:10.5056/jnm17090
28. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. DOI:10.1111/nmo.13330
29. Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet. Clin Gastroenterol Hepatol. 2020;18(4):767-76. DOI:10.1016/j.cgh.2019.07.015
30. Kahrilas P, Bredenoord A, Fox M, et al.; International High Resolution Manometry Working Group. The Сhicago classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160‐74. DOI:10.1111/nmo.12477
31. Yevsyutina YuV, Trukhmanov AS. Management of refractory GERD patients. RMJ. 2015;28:1682-3 (in Russian).
32. Kaybysheva VO, Storonova OA, Trukhmanov AS, Ivashkin VT. Intraesophageal pH-impedance measurement in diagnosis of GERD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;2:4-12 (in Russian).
33. Lottrup C, Krarup AL, Gregersen H, et al. Patients with Barrett’s esophagus are hypersensitive to acid but hyposensitive to other stimuli compared with healthy controls. Neurogastroenterol Motil. 2017;29(4). DOI:10.1111/nmo.12992
34. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12. DOI:10.1136/gut.37.1.7
35. Brandt MG, Darling GE, Miller L. Symptoms, acid exposure and motility in patients with Barrett’s esophagus. Can J Surg. 2004;47:47-51.
36. Grade A, Pulliam G, Johnson C, et al. Reduced chemoreceptor sensitivity in patients with Barrett’s esophagus may be related to age and not to the presence of Barrett’s epithelium. Am J Gastroenterol. 1997;92:2040-3.
37. Fletcher J, Gillen D, Wirz A, et al. Barrett’s esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions. Am J Gastroenterol. 2003;98:1480-6. DOI:10.1111/j.1572-0241.2003.07543.x
38. Weijenborg PW, Smout A, Krishnadath KK, et al. Esophageal sensitivity to acid in patients with Barrett’s esophagus is not related to preserved esophageal mucosal integrity. Neurogastroenterol Motil. 2017;29(7). DOI:10.1111/nmo.13066
39. Sanagapalli S, Emmanuel A, Leong R, et al. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018. DOI:10.1111/nmo.13330
40. Ivashkin VT, Maev IV, Trukhmanov AS, et al. High resolution manometry and new classification of esophageal motility disorders. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(5):93-100 (in Russian). DOI:10.26442/terarkh201890593-100
41. Maev IV, Andreev DN, Goncharenko AYu, Dicheva D.T. Proton pump inhibitors as the basis for the treatment of acid-related diseases. Handbook for Practitioners Doctors. 2013;7-8:42-4 (in Russian).
Авторы
И.В. Маев, Е.В. Баркалова*, Д.Н. Андреев, М.А. Овсепян, П.Р. Мовтаева, О.В. Зайратьянц
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*maslovaalena@mail.ru
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*maslovaalena@mail.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*maslovaalena@mail.ru
________________________________________________
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*maslovaalena@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.